Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects

Carmelo Blanquicett, M. Wasif Saif, Donald J. Buchsbaum, Mohamad Eloubeidi, Selwyn M. Vickers, David C. Chhieng, Mark D. Carpenter, Jeffrey C. Sellers, Suzanne Russo, Robert B Diasio, Martin R. Johnson

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Purpose: X-ray therapy (XRT) remains one of the major modalities used to treat patients diagnosed with locally advanced pancreatic adenocarcinoma. However, the effect of XRT on metastatic tumors outside the field of irradiation (abscopal effect) remains largely unknown. In the current study, we examined the effect of XRT alone and in combination with capecitabine and/or celecoxib in both irradiated and lead-shielded contralateral BxPC-3 pancreatic cancer xenografts. This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma. Experimental Design: Athymic mice were injected bilaterally with BxPC-3 cells and treatment was initiated 28 days postimplant. During XRT (2 Gy for 5 consecutive days, administered on days 0 and 24), one flank was irradiated whereas the rest of the body (including the contralateral tumor) was lead shielded. Capecitabine (350 mg/kg) was administered on days 0 to 13 and 24 to 37. Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p.o.) and administered throughout the study. Results: In irradiated xenografts, capecitabine and XRT showed synergistic anitiumor efficacy (P = 0.008), which was further improved with the addition of celecoxib (P < 0.001). In contralateral shielded xenografts, abscopal effects were observed. Whereas monotherapy with XRT showed significant reduction in tumor area in irradiated xenografts, growth was promoted by 23% (P < 0.001) in contralateral lead-shielded tumors in the same animals relative to untreated tumors. Interestingly, synergistic antiproliferative efficacy occurred in these contralateral tumors when capecitabine was administered (P < 0.001), despite being outside the irradiated field. The addition of celecoxib further inhibited tumor growth (P < 0.001). This trimodal combination most effectively stabilized disease in both shielded and irradiated tumors; however, tumor eradication was not observed. There were no significant changes in thymidine phosphorylase, dihydropyrimidine dehydrogenase, or cyclooxygenase-2 mRNA levels in irradiated or lead-shielded tumors, suggesting that efficacy cannot be predicted solely from these previously identified indicators of response. Immunohistochemistry examining the proliferation marker Ki-67 showed concordance with tumor response in both irradiated and contralateral shielded xenografts. Conclusions: These results have implications in the rational design of treatment paradigms for pancreatic cancer where metastatic disease remains the primary cause of patient morbidity and abscopal effects in tumors outside the field of irradiation may affect tumor response.

Original languageEnglish (US)
Pages (from-to)8773-8781
Number of pages9
JournalClinical Cancer Research
Volume11
Issue number24
DOIs
StatePublished - Dec 15 2005
Externally publishedYes

Fingerprint

Celecoxib
Pancreatic Neoplasms
Heterografts
X-Ray Therapy
Neoplasms
Lead
Capecitabine
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts : Clinical implications of abscopal effects. / Blanquicett, Carmelo; Saif, M. Wasif; Buchsbaum, Donald J.; Eloubeidi, Mohamad; Vickers, Selwyn M.; Chhieng, David C.; Carpenter, Mark D.; Sellers, Jeffrey C.; Russo, Suzanne; Diasio, Robert B; Johnson, Martin R.

In: Clinical Cancer Research, Vol. 11, No. 24, 15.12.2005, p. 8773-8781.

Research output: Contribution to journalArticle

Blanquicett, C, Saif, MW, Buchsbaum, DJ, Eloubeidi, M, Vickers, SM, Chhieng, DC, Carpenter, MD, Sellers, JC, Russo, S, Diasio, RB & Johnson, MR 2005, 'Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects', Clinical Cancer Research, vol. 11, no. 24, pp. 8773-8781. https://doi.org/10.1158/1078-0432.CCR-05-0627
Blanquicett, Carmelo ; Saif, M. Wasif ; Buchsbaum, Donald J. ; Eloubeidi, Mohamad ; Vickers, Selwyn M. ; Chhieng, David C. ; Carpenter, Mark D. ; Sellers, Jeffrey C. ; Russo, Suzanne ; Diasio, Robert B ; Johnson, Martin R. / Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts : Clinical implications of abscopal effects. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 24. pp. 8773-8781.
@article{57f441a89d094fb8b157190f1626fdda,
title = "Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects",
abstract = "Purpose: X-ray therapy (XRT) remains one of the major modalities used to treat patients diagnosed with locally advanced pancreatic adenocarcinoma. However, the effect of XRT on metastatic tumors outside the field of irradiation (abscopal effect) remains largely unknown. In the current study, we examined the effect of XRT alone and in combination with capecitabine and/or celecoxib in both irradiated and lead-shielded contralateral BxPC-3 pancreatic cancer xenografts. This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma. Experimental Design: Athymic mice were injected bilaterally with BxPC-3 cells and treatment was initiated 28 days postimplant. During XRT (2 Gy for 5 consecutive days, administered on days 0 and 24), one flank was irradiated whereas the rest of the body (including the contralateral tumor) was lead shielded. Capecitabine (350 mg/kg) was administered on days 0 to 13 and 24 to 37. Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p.o.) and administered throughout the study. Results: In irradiated xenografts, capecitabine and XRT showed synergistic anitiumor efficacy (P = 0.008), which was further improved with the addition of celecoxib (P < 0.001). In contralateral shielded xenografts, abscopal effects were observed. Whereas monotherapy with XRT showed significant reduction in tumor area in irradiated xenografts, growth was promoted by 23{\%} (P < 0.001) in contralateral lead-shielded tumors in the same animals relative to untreated tumors. Interestingly, synergistic antiproliferative efficacy occurred in these contralateral tumors when capecitabine was administered (P < 0.001), despite being outside the irradiated field. The addition of celecoxib further inhibited tumor growth (P < 0.001). This trimodal combination most effectively stabilized disease in both shielded and irradiated tumors; however, tumor eradication was not observed. There were no significant changes in thymidine phosphorylase, dihydropyrimidine dehydrogenase, or cyclooxygenase-2 mRNA levels in irradiated or lead-shielded tumors, suggesting that efficacy cannot be predicted solely from these previously identified indicators of response. Immunohistochemistry examining the proliferation marker Ki-67 showed concordance with tumor response in both irradiated and contralateral shielded xenografts. Conclusions: These results have implications in the rational design of treatment paradigms for pancreatic cancer where metastatic disease remains the primary cause of patient morbidity and abscopal effects in tumors outside the field of irradiation may affect tumor response.",
author = "Carmelo Blanquicett and Saif, {M. Wasif} and Buchsbaum, {Donald J.} and Mohamad Eloubeidi and Vickers, {Selwyn M.} and Chhieng, {David C.} and Carpenter, {Mark D.} and Sellers, {Jeffrey C.} and Suzanne Russo and Diasio, {Robert B} and Johnson, {Martin R.}",
year = "2005",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-05-0627",
language = "English (US)",
volume = "11",
pages = "8773--8781",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts

T2 - Clinical implications of abscopal effects

AU - Blanquicett, Carmelo

AU - Saif, M. Wasif

AU - Buchsbaum, Donald J.

AU - Eloubeidi, Mohamad

AU - Vickers, Selwyn M.

AU - Chhieng, David C.

AU - Carpenter, Mark D.

AU - Sellers, Jeffrey C.

AU - Russo, Suzanne

AU - Diasio, Robert B

AU - Johnson, Martin R.

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Purpose: X-ray therapy (XRT) remains one of the major modalities used to treat patients diagnosed with locally advanced pancreatic adenocarcinoma. However, the effect of XRT on metastatic tumors outside the field of irradiation (abscopal effect) remains largely unknown. In the current study, we examined the effect of XRT alone and in combination with capecitabine and/or celecoxib in both irradiated and lead-shielded contralateral BxPC-3 pancreatic cancer xenografts. This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma. Experimental Design: Athymic mice were injected bilaterally with BxPC-3 cells and treatment was initiated 28 days postimplant. During XRT (2 Gy for 5 consecutive days, administered on days 0 and 24), one flank was irradiated whereas the rest of the body (including the contralateral tumor) was lead shielded. Capecitabine (350 mg/kg) was administered on days 0 to 13 and 24 to 37. Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p.o.) and administered throughout the study. Results: In irradiated xenografts, capecitabine and XRT showed synergistic anitiumor efficacy (P = 0.008), which was further improved with the addition of celecoxib (P < 0.001). In contralateral shielded xenografts, abscopal effects were observed. Whereas monotherapy with XRT showed significant reduction in tumor area in irradiated xenografts, growth was promoted by 23% (P < 0.001) in contralateral lead-shielded tumors in the same animals relative to untreated tumors. Interestingly, synergistic antiproliferative efficacy occurred in these contralateral tumors when capecitabine was administered (P < 0.001), despite being outside the irradiated field. The addition of celecoxib further inhibited tumor growth (P < 0.001). This trimodal combination most effectively stabilized disease in both shielded and irradiated tumors; however, tumor eradication was not observed. There were no significant changes in thymidine phosphorylase, dihydropyrimidine dehydrogenase, or cyclooxygenase-2 mRNA levels in irradiated or lead-shielded tumors, suggesting that efficacy cannot be predicted solely from these previously identified indicators of response. Immunohistochemistry examining the proliferation marker Ki-67 showed concordance with tumor response in both irradiated and contralateral shielded xenografts. Conclusions: These results have implications in the rational design of treatment paradigms for pancreatic cancer where metastatic disease remains the primary cause of patient morbidity and abscopal effects in tumors outside the field of irradiation may affect tumor response.

AB - Purpose: X-ray therapy (XRT) remains one of the major modalities used to treat patients diagnosed with locally advanced pancreatic adenocarcinoma. However, the effect of XRT on metastatic tumors outside the field of irradiation (abscopal effect) remains largely unknown. In the current study, we examined the effect of XRT alone and in combination with capecitabine and/or celecoxib in both irradiated and lead-shielded contralateral BxPC-3 pancreatic cancer xenografts. This chemoradiation regimen was chosen based on our molecular analysis of pancreatic adenocarcinoma. Experimental Design: Athymic mice were injected bilaterally with BxPC-3 cells and treatment was initiated 28 days postimplant. During XRT (2 Gy for 5 consecutive days, administered on days 0 and 24), one flank was irradiated whereas the rest of the body (including the contralateral tumor) was lead shielded. Capecitabine (350 mg/kg) was administered on days 0 to 13 and 24 to 37. Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p.o.) and administered throughout the study. Results: In irradiated xenografts, capecitabine and XRT showed synergistic anitiumor efficacy (P = 0.008), which was further improved with the addition of celecoxib (P < 0.001). In contralateral shielded xenografts, abscopal effects were observed. Whereas monotherapy with XRT showed significant reduction in tumor area in irradiated xenografts, growth was promoted by 23% (P < 0.001) in contralateral lead-shielded tumors in the same animals relative to untreated tumors. Interestingly, synergistic antiproliferative efficacy occurred in these contralateral tumors when capecitabine was administered (P < 0.001), despite being outside the irradiated field. The addition of celecoxib further inhibited tumor growth (P < 0.001). This trimodal combination most effectively stabilized disease in both shielded and irradiated tumors; however, tumor eradication was not observed. There were no significant changes in thymidine phosphorylase, dihydropyrimidine dehydrogenase, or cyclooxygenase-2 mRNA levels in irradiated or lead-shielded tumors, suggesting that efficacy cannot be predicted solely from these previously identified indicators of response. Immunohistochemistry examining the proliferation marker Ki-67 showed concordance with tumor response in both irradiated and contralateral shielded xenografts. Conclusions: These results have implications in the rational design of treatment paradigms for pancreatic cancer where metastatic disease remains the primary cause of patient morbidity and abscopal effects in tumors outside the field of irradiation may affect tumor response.

UR - http://www.scopus.com/inward/record.url?scp=29344445640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344445640&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0627

DO - 10.1158/1078-0432.CCR-05-0627

M3 - Article

C2 - 16361565

AN - SCOPUS:29344445640

VL - 11

SP - 8773

EP - 8781

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -